Advanced Search
MyIDEAS: Login

Understanding the costs of care for cystic fibrosis: an analysis by age and severity. CHERE Working Paper 2011/1

Contents:

Author Info

  • Kees Van Gool
  • Richard Norman

    ()
    (CHERE, University of Technology, Sydney)

  • Martin B Delatycki
  • Jane Hall

    ()
    (CHERE, University of Technology, Sydney)

  • John Massie

Abstract

Cystic fibrosis (CF) is the most common life-shortening genetic disease, with an incidence of 1 in 2500 and carrier frequency of 1 in 25, amongst Caucasians (Welsh, Ramsey et al. 2001). With recent advances in treatment, most children with CF now can expect to survive into adulthood and life expectancy has improved considerably. CF is a progressive disease which affects many organ systems and as the disease progresses patients require more intensive health care that includes home based care and medications, along with more frequent and prolonged hospital admissions, and in around half of all cases lung transplantation.(Jason, Leah et al. 2009; Paul, Leah et al. 2009). As new and improving treatment options become available, the pattern of care will change, which will impact on the costs of treatment and on patient outcomes. For example, two of the key medications developed in the last 15 years, Pulmozyme and TOBI (not licensed for use in Australia) cost A$14,000 pa; and more sophisticated technology, such as gene-based treatments will be equally, or more expensive. Thus health care policy makers and funders will expect rigorous assessments of the cost-effectiveness of new treatments.

Download Info

If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
File URL: http://www.chere.uts.edu.au/pdf/wp2011_1.pdf
File Function: First version,
Download Restriction: no

Bibliographic Info

Paper provided by CHERE, University of Technology, Sydney in its series Working Papers with number 2011/1.

as in new window
Length:
Date of creation: Mar 2011
Date of revision:
Handle: RePEc:her:chewps:2011/1

Contact details of provider:
Postal: Level 4, 645 Harris Street, Ultimo, NSW 2007
Phone: +61 2 9514 9799
Fax: 61 2 9514 4730
Email:
Web page: http://www.chere.uts.edu.au
More information through EDIRC

Related research

Keywords: Cystic Fibrosis; costs; cost effectiveness;

Find related papers by JEL classification:

This paper has been announced in the following NEP Reports:

References

No references listed on IDEAS
You can help add them by filling out this form.

Citations

Lists

This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.

Statistics

Access and download statistics

Corrections

When requesting a correction, please mention this item's handle: RePEc:her:chewps:2011/1. See general information about how to correct material in RePEc.

For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Liz Chinchen).

If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

If references are entirely missing, you can add them using this form.

If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.

If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.

Please note that corrections may take a couple of weeks to filter through the various RePEc services.